Colorectal Cancer

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Arvind Dasari, MD, MS, discusses considerations and challenges associated with treating patients in the later-line colorectal cancer setting.

The NuTide:323 trial of NUC-3373 plus leucovorin, irinotecan, and bevacizumab in second-line colorectal cancer has been discontinued.

Arvind N. Dasari, MD, MS, discusses later-line treatment considerations for patients with unresectable metastatic colorectal cancer.

Arvind Dasari, MD, MS, discusses fruquintinib as later-line treatment for patients with advanced metastatic colorectal cancer.

Oxaliplatin plus fluoropyrimidine and bevacizumab confers little therapeutic benefit to older patients with metastatic colorectal cancer.

John H. Strickler, MD, discusses the significance of fruquintinib for patients with metastatic colorectal cancer who have exhausted standard therapies.

Michael Cecchini, MD, discusses findings from the ARC-9 trial investigating an etrumadenant-based combination in patients with previously treated mCRC.

Drs Park and Kasi delve into the shift toward neoadjuvant immunotherapy and the use of ctDNA as a prognostic tool in colorectal cancer.

Aparna Parikh, MD, discusses the rationale for adding ERAS-007 to the BEACON regimen in BRAF V600E–mutated metastatic colorectal cancer.

Rona Yaeger, MD, details the FDA approval of adagrasib plus cetuximab in KRAS G12C-mutated colorectal cancer and how the approval will advance the field.

Richard Kim, MD, discusses the current treatment paradigm for patients with resectable CRC, as well as unmet needs in this population.

Eric S. Christenson, MD, discusses the safety of copanlisib plus nivolumab in pretreated, PIK3Ca-mutated microsatellite stable, unresectable or metastatic colorectal cancer.

The Guardant Reveal test was accurate in predicting disease recurrence in stage II or higher colorectal cancer.

ABBV-400 displayed efficacy and tolerability in microsatellite stable/mismatch repair–proficient advanced colorectal cancer.

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

The Shield blood test has been approved by the FDA for CRC screening in adults aged 45 years and older who are at average risk for the disease.

Richard Kim, MD, discusses the standard treatment approaches and unmet needs for patients with resectable colorectal cancer.

The FDA completed an end-of-phase 2 meeting for botensilimab plus balstilimab in relapsed/refractory microsatellite stable colorectal cancer.

Tanios S. Bekaii-Saab, MD, highlights data from the phase 1/2 ARC-9 study which showed promising overall survival data in patients with colorectal cancer.

Here is your guide to the important regulatory decisions made by the FDA in June 2024.

Pembrolizumab plus bevacizumab and CAPOX produced responses in pMMR/MSS metastatic colorectal cancer with high immune infiltrate.

Botensilimab and balstilimab demonstrated pathological responses across subsets of patients with resectable colon cancer.

In case you missed any, below is a recap of every OncLive On Air episode that aired in June 2024.

Aparna Parikh, MD, discusses key findings from the HERKULES-3 study and what the future of the BRAF-mutated mCRC treatment paradigm may look like.